TacticScaleWhat Baxter International Does & How It Makes Money (BAX)
Updated October 2026 · reflects Baxter International's latest reported financials
Diversified maker of hospital products, IV therapies, and injectable drugs. Baxter earns revenue by selling medical devices, consumable supplies, and injectable pharmaceuticals to healthcare providers through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacies.
How Baxter International makes money
Baxter earns revenue by selling medical devices, consumable supplies, and injectable pharmaceuticals to healthcare providers through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacies. Much of its portfolio consists of products that are used up and reordered, such as IV solutions and drugs, alongside equipment like infusion systems, beds, and monitors.
What Baxter International does
Baxter International is a long-established U.S. healthcare company, incorporated in 1931 and headquartered in Deerfield, Illinois. It reports in three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. Its core business covers basic hospital care products, including sterile IV solutions, infusion systems, parenteral nutrition, and inhaled anesthetics. The company also sells surgical hemostats and sealants, operating room integration and patient positioning equipment, smart beds, patient monitoring and diagnostic technologies, and respiratory devices. On the pharmaceutical side, it offers generic and specialty injectable drugs and drug compounding services. Its products are sold through direct and distributor channels to hospitals, surgery centers, dialysis centers, and home-care settings in the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
Products & services
- Sterile IV solutions
- Infusion systems and devices
- Parenteral nutrition therapies
- Inhaled anesthetics
- Surgical hemostat and sealant products
- Smart bed systems and patient monitoring
What is Baxter International worth?
On an owner-earnings DCF, Baxter International's most-likely value is about $26 versus a recent price near $24 (8% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$17) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 9.1× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Becton, Dickinson and (BDX) · Abbott Laboratories (ABT) · ICU Medical (ICUI) · Boston Scientific (BSX) · Teleflex (TFX)